Acurx Pharmaceuticals, Inc.
ACXPHealthcare|Biotechnology|US
$1.06
+0.11 (+12.09%)
DCF Value
$5.07
Tangible Book / Share
$1.91
Cash / Share
$2.50
Financials
Financial Snapshot
Market Cap
$5.9M
Enterprise Value
-$4.8M
Revenue (TTM)
$0.00
Net Income (TTM)
-$7.5M
Cash & Investments
$10.7M
Net Cash
$10.7M
Free Cash Flow (TTM)
-$6.2M
Operating CF (TTM)
-$6.2M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$10.7M
Quarterly Burn
$1.5M
Monthly Burn
$515.3K
Est. Runway
~6.9 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.5M | $3.2M | $13.0M | $9.1M | $7.5M | $3.7M | $7.6M | $10.7M | |
| Operating Cash Flow | -$4.0M | -$3.4M | -$5.0M | -$7.5M | -$9.8M | -$10.4M | -$6.8M | -$6.2M | |
| Free Cash Flow | -$4.0M | -$3.4M | -$5.0M | -$7.5M | -$9.8M | -$10.4M | -$6.8M | -$6.2M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $4.5M | $4.0M | $14.8M | $3.7M | $8.2M | $6.6M | $10.6M | $10.8M |
R&D Spending
R&D (TTM)
$1.83B
R&D Intensity
—
R&D Growth vs Prior
+0.0%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $3.5M | $2.2M | $2.0M | $4.8M | $6.0M | $5.4M | $1.83B | $1.83B | |
| SG&A | $2.4M | $2.4M | $10.8M | $7.3M | $8.5M | $8.7M | $6.26B | $7.63B |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $3.5M | $2.2M | $2.0M | $4.8M | $6.0M | $5.4M | $1.83B | $1.83B | |
| SG&A | $2.4M | $2.4M | $10.8M | $7.3M | $8.5M | $8.7M | $6.26B | $7.63B | |
| Operating Income | -$5.9M | -$4.6M | -$12.8M | -$12.1M | -$14.6M | -$14.1M | -$8.1M | -$7.7M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$5.9M | -$4.6M | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M | -$7.5M | |
| Net Income | -$5.9M | -$4.6M | -$12.7M | -$12.1M | -$14.6M | -$14.1M | -$8.0M | -$7.5M | |
| EPS (Diluted) | -12.00 | -9.28 | -24.96 | -22.36 | -23.01 | -17.59 | -5.32 | -3.55 | |
| EBITDA | $0.00 | $0.00 | -$12.7M | -$12.1M | -$14.6M | $20.1K | -$8.0M | -$7.6M | |
| Shares Out. (M) | 0.48 | 0.50 | 0.51 | 0.54 | 0.63 | 0.85 | 1.50 | 4.26 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.5M | $3.2M | $13.0M | $9.1M | $7.5M | $3.7M | $7.6M | $10.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.5M | $3.2M | $13.3M | $9.4M | $7.7M | $3.9M | $7.7M | $11.0M | |
| Total Assets | $2.5M | $3.2M | $13.3M | $9.4M | $7.7M | $3.9M | $7.7M | $11.0M | |
| Total Current Liabilities | $1.7M | $472.6K | $843.9K | $2.1M | $3.0M | $3.2M | $2.4M | $2.8M | |
| Long-Term Debt | $0.00 | $49.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.7M | $522.4K | $843.9K | $2.1M | $3.0M | $3.2M | $2.4M | $2.8M | |
| Stockholders' Equity | $819.9K | $2.7M | $12.4M | $7.3M | $4.7M | $615.1K | $5.3M | $8.2M | |
| Retained Earnings | -$9.2M | -$13.8M | -$26.5M | -$38.6M | -$53.2M | -$67.3M | -$75.3M | -$79.2M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.0M | -$3.4M | -$5.0M | -$7.5M | -$9.8M | -$10.4M | -$6.8M | -$6.2M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$4.0M | -$3.4M | -$5.0M | -$7.5M | -$9.8M | -$10.4M | -$6.8M | -$6.2M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $4.5M | $4.0M | $14.8M | $3.7M | $8.2M | $6.6M | $10.6M | $10.8M | |
| Issuance of Stock | $4.5M | $4.0M | $14.8M | $3.7M | $5.9M | $6.4M | $10.6M | $10.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0K | $0.00 | |
| Net Debt Issuance | $0.00 | $66.5K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $900.4K | $1.3M | $6.7M | $3.3M | $3.8M | $3.4M | $1.6M | $1.0M | |
| Net Change in Cash | $470.2K | $692.1K | $9.8M | -$3.8M | -$1.6M | -$3.8M | $3.8M | $4.6M |
Dilution Tracker
Shares outstanding grew 202.3% over 5 years — significant dilution
Shares Outstanding
6M
5-Year Share Growth
+202.3%
Stock Issuance (TTM)
$10.8M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.48 | 0.50 | 0.51 | 0.54 | 0.63 | 0.85 | 1.50 | 4.26 | |
| Change vs Prior % | — | 3.9% | 3.0% | 5.9% | 17.2% | 34.4% | 76.0% | 184.2% | |
| Stock Issuance | $4.5M | $4.0M | $14.8M | $3.7M | $5.9M | $6.4M | $10.6M | $10.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0K | $0.00 | |
| Stock Based Comp. | $900.4K | $1.3M | $6.7M | $3.3M | $3.8M | $3.4M | $1.6M | $1.0M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | -723.5% | -170.3% | -102.7% | -165.3% | -312.4% | -2292.7% | -151.2% | -124.7% | |
| ROA % | -234.3% | -142.7% | -96.2% | -129.0% | -189.1% | -365.6% | -103.6% | -68.3% | |
| ROIC % | -723.5% | -166.2% | -103.3% | -165.3% | -312.4% | -2292.7% | -153.6% | -94.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 22.4% | -178.6% | 5.6% | -20.5% | 3.3% | 42.6% | |
| Net Income | 0.0% | 22.4% | -177.1% | 5.1% | -20.5% | 3.3% | 43.5% | |
| EPS (Diluted) | 0.0% | 22.7% | -169.0% | 10.4% | -2.9% | 23.6% | 69.8% | |
| Operating Cash Flow | 0.0% | 15.9% | -49.6% | -50.4% | -29.9% | -5.9% | 34.6% | |
| Free Cash Flow | 0.0% | 15.9% | -49.6% | -50.4% | -29.9% | -5.9% | 34.6% | |
| R&D Expense | 0.0% | -37.2% | -7.8% | 134.2% | 27.1% | -10.6% | 33848.2% | |
| SG&A Expense | 0.0% | -1.0% | 349.9% | -32.0% | 16.3% | 1.9% | 71831.1% | |
| Total Assets | 0.0% | 27.4% | 311.1% | -29.3% | -17.8% | -50.0% | 99.3% | |
| Book Value / Share | 0.0% | 149.3% | 345.9% | -44.3% | -45.5% | -90.2% | 386.6% | |
| Debt | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 3.9% | 3.0% | 5.9% | 17.2% | 34.4% | 76.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.55
10Y Low / Med / High0.71 / 10.40 / 72.20
EV/EBITDA0.63
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$5.07
Tangible Book / Share
$1.91
Net Current Assets / Share
$1.47
Graham Net-Net
$1.85
Cash / Share
$2.50
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -13.15 | -17.00 | -3.46 | -3.56 | -3.33 | -0.93 | -0.47 | -0.30 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 72.20 | 28.96 | 3.56 | 5.88 | 10.40 | 22.54 | 0.71 | 0.55 | |
| EV/EBITDA | 0.00 | 0.00 | -2.45 | -2.81 | -2.82 | 504.70 | 0.48 | 0.63 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-10.23
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $276.0K | $3.5M | $25.3M |
| Net Income | -$2.6M | -$2.2M | -$2.6M |
| EPS | $-1.72 | $-1.50 | $-1.75 |
| # Analysts (EPS) | 1 | 1 | 1 |